EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	108.85M
Revenue (ttm)	50.22M
Net Income (ttm)	6.12M
Shares Out	435.38M
EPS (ttm)	0.01
PE Ratio	18.51
Forward PE	17.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,809
Average Volume	421,973
Open	24.90
Previous Close	25.00
Day's Range	24.00 - 25.00
52-Week Range	18.40 - 32.00
Beta	0.59
RSI	47.53
Earnings Date	Dec 17, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 303
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.